Revenue beats, profit misses; long-term diversification intact but near-term margin pain

Revenue grew 30.1% YoY to ₹356.5 Cr, matching claim

Organic revenue (ex-Ascent) ~10% aligns with disclosed figures

PAT declined 2.6% YoY to ₹75.2 Cr; understates severity (QoQ -7.3%)

EBITDA growth 7.1% YoY; consolidated EBITDA margin fell to 34.2% from ~37%

Ascent revenue grew to US$5.9M from US$4.4M (32% YoY), ~200% with contribution counted

Delivered 30.1% YoY (largely driven by Ascent acquisition, organic ~10%)

PAT declined 2.6% YoY; miss of 12.6 percentage points vs guidance

Prior FY26 call: 10% PAT growth expected. Q1 delivered -2.6% YoY. Now guidance 12-15% FY27 CAGR (recovery assumed). Credibility hit; requires flawless H2 execution.

Reaffirmed 17-20% EBITDA growth, 12-15% PAT growth (vs prior high single digit). Upgrade reflects confidence in Q2+ cost optimization, but current quarter miss tempers enthusiasm.

Still targeting double-digit EBITDA within 12 months, not next quarter. Better-than-plan cost management (broke even Q4 FY26 at 8.4%, vs plan for H2), but no acceleration announced.

Now 38% of revenue (vs 24.5% prior year). International organic +32%. Pensions CRA revenue ₹17Cr (from ₹3Cr 3.5 years ago). Validates multi-year strategy; positively surprises vs initial skepticism.

Prior guidance implied pricing discipline would stabilize yields. Q1 saw 2% QoQ decline; 30% from asset mix shift (debt→liquid), 1.7% from contract provisions. Pricing power exists but insufficient offset.

Cost optimization through technology (XAlt, Suprema upgrades), payroll efficiency via full increments + productivity gains, and IT licensing optimization. SIP automation launched (3-day processing, 99.7% within target vs 21 days industry norm). Bigger optimization items yet to come.

Both. Ascent at 7-8% EBITDA; faster top-line growth even at 8% offsets some PAT drag from amortization/capitalization. KFin cost optimization is focus; Ascent focus remains market share expansion, not cost-cutting. Two-to-three year path to double-digit EBITDA.

~30% from debt-to-liquid shift (debt yields 2-2.5x liquid), ~1.7% net of asset class movement from contract provisions and renegotiation provisions. Equity AUM stable QoQ. Pricing discipline on discount believed sufficient for stabilization forward.

One-quarter phenomena; contracts in pipeline will materialize coming quarters. International business expected to grow >25% ongoing; not a fundamental change.

Deals episodic, not annuity; some close in 3 months, some 15 months. Cannot break down by quarter but IR team can help model. Total INR 40Cr across varying timeframes.

Six new fund manager mandates >$100M won this quarter. These are transitions (no new fund manager starts at $100M accumulated corpus). Transition typically 3-5 months. Names withheld pending separate call.

Upgraded: EBITDA growth 17-20%, PAT growth 12-15% visibility on FY27 CAGR basis. Better than initially forecasted confidence.

Ascent revenue grew Q4 US$5.7M to Q1 US$5.9M (modest dollar growth). 32% YoY (vs US$4.4M Q1 FY26). Growth driven by new client wins and corporate solutions, not just rupee tailwind.

Assumptions directionally right. Southeast Asia AUM growth this quarter helped margins/bps (unusual for region). Hope trajectory continues; represents improved yield trajectory.

No contract awarded yet. Media leak identified KFin as highest bidder technical/commercial. Still under discussion with client. Cannot forecast timing or profitability at this stage.

IPOs help, but corporate actions (30% of revenue) tepid from IT services dividend cuts. Retail investor participation still muted despite market recovery. Unit economics depend on folio growth + corporate actions both; currently both tepid. Hopeful but not confident.

Connect with IR team; they will provide segment P&L details. [Deflection.]

Two models: (1) Fixed-fee platform implementation followed by 20-35% AMC of contract value (based on complexity). (2) Basis points on AUM, like mutual funds. Differentiates KFin from incumbents who license platform only; KFin provides full service.

Supported by 10% organic + diversification (non-MF 40% now). Ascent contribution expected 5-10pp. Robust order book cited but not quantified.

Top-line guided by current +30% run-rate; guidance implies deceleration to 18-20% in later years as Ascent ramps down organic growth and margin expansion kicks in.

Currently 34.2% consolidated (39.4% ex-Ascent). Ascent drag expected to ease as 8.4% EBITDA reaches double digits. Cost optimization initiatives visible Q2+. Timing ambitious but realistic by FY28 end.

Current -2.6% YoY PAT decline is near 15pp gap to guidance. Requires flawless H2 execution, Ascent ramp, cost takeouts realized, and no further market headwinds. Credibility eroded.

Management guided 'several strategic initiatives' for cost optimization with quarter-delay fruition. Q2+ should show PAT recovery from capitalization absorption + operational leverage.

Ascent at 8.4% EBITDA margin; double-digit target within 12 months is aggressive. Digital asset fund markdowns and crypto market weakness offset new client wins. Amortization and One Constellation capex dragging consolidated PAT.

2% QoQ yield decline from asset mix shift (debt→liquid due to geopolitics, not equity to passive). Management claims pricing power but unable to guide forward yield. Contract renewal provisions indicate 1.7% headwind still embedded.

Corporate actions (dividends, buybacks, splits) represent ~30% of issuer solutions revenue. IT services companies (major constituents) have deferred dividends in Q1. Management guided 'slightly tepid' Q2 trajectory.

One large contract due for renewal this year with provisions already made for price negotiation. Domestic MF market share concentrated (50% NSE 500, leading position). Ascent's larger fund manager wins dependent on retention post-transition (3-5 months critical period).

Philippines BPI contract: KFin identified as highest bidder (technical + commercial) but not yet awarded; timeline and final terms unclear. Cayman facility opening is regulatory requirement (substance rule) with upfront costs and execution risk.